Search results for "Marker"

showing 10 items of 3799 documents

The EU-funded I3LUNG Project:Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

2023

Although immunotherapy (IO) has changed the paradigm for the treatment of patients with advanced non-small cell lung cancers (aNSCLC), only around 30% to 50% of treated patients experience a long-term benefit from IO. Furthermore, the identification of the 30 to 50% of patients who respond remains a major challenge, as programmed Death-Ligand 1 (PD-L1) is currently the only biomarker used to predict the outcome of IO in NSCLC patients despite its limited efficacy. Considering the dynamic complexity of the immune system-tumor microenvironment (TME) and its interaction with the host's and patient's behavior, it is unlikely that a single biomarker will accurately predict a patient's outcomes. …

Pulmonary and Respiratory MedicineCancer ResearchArtificial intelligenceOncologyNon-small cell lung cancerPredictive biomarkersMachine learningPersonalized medicine
researchProduct

A particular phenotype of ascending aorta aneurysms as precursor of type A aortic dissection.

2012

Objectives: We aimed to identify a phenotype of ascending thoracic aortic aneurysm (TAA), which, more than others, evolves into type A dissection (TAD). Methods: Aortic specimens were obtained from patients undergoing surgical repair of TAA and TAD (108 and 26, respectively). Histopathological and immunohistochemical analyses were performed by using adequate tissue specimens, appropriate techniques and criteria. Results: We identified the three following TAA phenotypes: phenotype I (cystic medial degeneration balanced by a substitutive fibrosis, in absence of medial apoptosis and with a faint collagenase concentration), phenotype II (cystic medial degeneration of higher grade, respectively,…

Pulmonary and Respiratory MedicineMalePathologymedicine.medical_specialtyAorta ThoracicApoptosisThoracic aortic aneurysmAortic aneurysmAneurysmFibrosismedicine.arteryAscending aortamedicineSettore MED/05 - Patologia ClinicaThoracic aortaHumansAgedAortic dissectionAortaAortic Aneurysm Thoracicbusiness.industryDissectionSettore MED/23 - Chirurgia CardiacaOriginal ArticlesMiddle Agedmedicine.diseasePrognosisAneurysmFibrosisImmunohistochemistryAortic DissectionPhenotypeMatrix Metalloproteinase 9Disease ProgressionSurgeryFemaleThoracic aortic aneurysm phenotype IIICardiology and Cardiovascular MedicinebusinessAneurysm ; Dissection ; Thoracic aortic aneurysm phenotype IIIBiomarkersInteractive cardiovascular and thoracic surgery
researchProduct

Cardioprotective effects of the serine protease inhibitor aprotinin after regional ischemia and reperfusion on the beating heart.

2002

AbstractObjective: Early coronary reperfusion of the ischemic myocardium is a desired therapeutic goal to preserve myocardium. However, reperfusion itself contributes to an additional myocardial injury (ie, reperfusion injury), which has been attributed to neutrophil infiltration with subsequent release of proteases and oxygen-derived radicals. We studied the effects of the serine protease inhibitor aprotinin (Trasylol) on myocardial ischemia and reperfusion in a rat model. Methods: The effects of aprotinin (5000 and 20,000 U/kg) were examined in vivo in a rat model of regional myocardial ischemia (20 minutes) and long-term reperfusion (24 hours). Cardioprotecive effects were determined by …

Pulmonary and Respiratory MedicineMaleProteasesCardiotonic AgentsSerine Proteinase InhibitorsNeutrophilsHeart VentriclesIschemiaMyocardial IschemiaApoptosisMyocardial ReperfusionMyocardial Reperfusion InjuryPharmacologyRats Sprague-DawleyLeukocyte CountAprotininIn vivoMedicineAnimalsAprotininCreatine KinasePeroxidaseCardioprotectionbiologyDose-Response Relationship Drugbusiness.industryMyocardiumModels Cardiovascularmedicine.diseaseCombined Modality TherapyRatsDisease Models AnimalTreatment OutcomeEnzyme inhibitorAnesthesiabiology.proteinSurgeryCreatine kinaseCardiology and Cardiovascular MedicinebusinessReperfusion injuryBiomarkersmedicine.drugThe Journal of thoracic and cardiovascular surgery
researchProduct

C-reactive Protein Levels After Esophagectomy Are Associated With Increased Surgical Trauma and Complications.

2020

With the introduction of minimally invasive esophagectomy, postoperative complications rates have decreased. Daily laboratory tests are used to screen patients for postoperative complications. The course of inflammatory indicators after esophagectomy after different surgical approaches has not been described yet. The aim of the study was to describe the postoperative C-reactive protein (CRP) and leukocyte levels after different surgical approaches for esophagectomy and relate it to postoperative complications.Between 2010 and 2018, 217 consecutive patients underwent thoracoabdominal esophagectomy with gastric conduit reconstruction. Blood tests to assess CRP and leukocytes were performed da…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyMultivariate analysisEsophageal Neoplasmsmedicine.medical_treatment030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePostoperative ComplicationsGermanyBiomarkers TumorMedicineHumansMinimally Invasive Surgical ProceduresPostoperative PeriodMinimally invasive proceduresRetrospective StudiesSurgical approachbiologybusiness.industryGastric conduitIncidence (epidemiology)IncidenceC-reactive proteinRetrospective cohort studyMiddle AgedSurgeryEsophagectomyC-Reactive Protein030228 respiratory systemEsophagectomybiology.proteinSurgeryFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesThe Annals of thoracic surgery
researchProduct

Patterns and diagnostic value of cardiac troponin I vs. troponin T and CKMB after OPCAB surgery.

2001

Cardiac troponin I (cTnI) has been shown to be a specific marker for myocardial injury in cardiac surgery. The object of this prospective study was to determine the patterns and kinetic and diagnostic value of cTnI, cardiac troponin T (cTnT), and creatine kinase MB (CKMB) activity after minimally invasive coronary revascularization using an octopus device on the beating heart (OPCAB).48 patients (33 male/15 female, mean age 68.3 +/- 8.7 years) underwent their first elective OPCAB surgery with median sternotomy without mortality. The mean number of grafts was 2.0 +/- 0.8 per patient. Preoperative mean ejection fraction was 56.6 % +/- 14.9%. CTnI and T levels, total creatine kinase (CK) and C…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyMyocardial Infarctionmacromolecular substancesSensitivity and SpecificityElectrocardiographyTroponin complexTroponin TInternal medicineTroponin ImedicineMyocardial RevascularizationCreatine Kinase MB FormHumanscardiovascular diseasesProspective StudiesRadionuclide ImagingCreatine KinaseVascular PatencyAgedEjection fractionbiologyTroponin Tbusiness.industryTroponin IPerioperativeMiddle Agedmusculoskeletal systemMagnetic Resonance ImagingCardiac surgerySurgeryIsoenzymesROC Curvecardiovascular systemCardiologybiology.proteinSurgeryCreatine kinaseFemaleMyocardial infarction diagnosisCardiology and Cardiovascular MedicinebusinessBiomarkersThe Thoracic and cardiovascular surgeon
researchProduct

Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers.

2019

Background Community-acquired pneumonia (CAP) increases the risk of cardiovascular complications during and following the episode. The goal of this study was to determine the usefulness of cardiovascular and inflammatory biomarkers for assessing the risk of early (within 30 days) or long-term (1-year follow-up) cardiovascular events. Methods A total of 730 hospitalized patients with CAP were prospectively followed up during 1 year. Cardiovascular (proadrenomedullin [proADM], pro-B-type natriuretic peptide (proBNP), proendothelin-1, and troponin T) and inflammatory (interleukin 6 [IL-6], C-reactive protein, and procalcitonin) biomarkers were measured on day 1, at day 4/5, and at day 30. Resu…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyTime Factorsmedicine.drug_classCritical Care and Intensive Care MedicineRisk AssessmentProcalcitonin03 medical and health sciences0302 clinical medicineCommunity-acquired pneumoniaInternal medicineNatriuretic peptidePneumonia BacterialMedicineHumans030212 general & internal medicineMyocardial infarctionProspective StudiesAgedAged 80 and overbiologyTroponin Tbusiness.industryC-reactive proteinMiddle Agedmedicine.diseaseTroponinCommunity-Acquired InfectionsPneumonia030228 respiratory systemCardiovascular Diseasesbiology.proteinCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersChest
researchProduct

Prognostic impact of copeptin in pulmonary embolism: a multicentre validation study.

2018

To externally validate the prognostic impact of copeptin, either alone or integrated in risk stratification models, in pulmonary embolism (PE), we performed a post hoc analysis of 843 normotensive PE patients prospectively included in three European cohorts.Within the first 30 days, 21 patients (2.5%, 95% CI 1.5–3.8) had an adverse outcome and 12 (1.4%, 95% CI 0.7–2.5) died due to PE. Patients with copeptin ≥24 pmol·L−1 had a 6.3-fold increased risk for an adverse outcome (95% CI 2.6–15.5, p<0.001) and a 7.6-fold increased risk for PE-related death (95% CI 2.3–25.6, p=0.001). Risk classification according to the 2014 European Society of Cardiology (ESC) guideline algorithm identified 248…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyValidation studyAdverse outcomes030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineCopeptinRisk groupsRisk FactorsInternal medicinePost-hoc analysismedicineHumansProspective StudiesAgedAged 80 and overbusiness.industryGlycopeptidesMiddle Agedmedicine.diseasePrognosisPulmonary embolismIncreased riskLogistic Models030228 respiratory systemROC CurveRisk stratificationFemalebusinessPulmonary EmbolismAlgorithmsBiomarkersThe European respiratory journal
researchProduct

Introducing the new biomarker research approach into practice: Preliminary data from CXCL4 chemokine study in non-small cell lung cancer (NSCLC)

2012

Pulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyOncologybusiness.industryInternal medicinemedicineBiomarker (medicine)non-small cell lung cancer (NSCLC)medicine.diseasebusinessPlatelet factor 4Lung Cancer
researchProduct

P2.04-10 Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients

2018

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyOncologyBlood biomarkersbusiness.industryInternal medicinemedicineNivolumabbusinessJournal of Thoracic Oncology
researchProduct

An Official American Thoracic Society Workshop Report: Evaluation and Management of Asthma in the Elderly.

2016

Asthma in the elderly (>65 yr old) is common and associated with higher morbidity and mortality than asthma in younger patients. The poor outcomes in this group are due, in part, to underdiagnosis and undertreatment. There are a variety of factors related to aging itself that affect the presentation of asthma in the elderly and influence diagnosis and management. Structural changes in the aging lung superimposed on structural changes due to asthma itself can worsen the disease and physiologic function. Changes in the aging immune system influence the cellular composition and function in asthmatic airways. These processes and differences from younger individuals with asthma are not well u…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAgingImmunosenescenceaging; immunosenescence; lung function; phenotype; reactive airways diseaseDiseaseComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)Diagnosis Differential03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineimmune system diseasesreactive airways diseasemedicineHumans030212 general & internal medicineDisease management (health)LungSocieties MedicalAsthmaAgedAmerican Thoracic Society DocumentsLungbusiness.industryDisease Managementlung functionImmunosenescencemedicine.diseaseComorbidityAsthmaUnited Statesrespiratory tract diseasesmedicine.anatomical_structurePhenotype030228 respiratory systemPhysical therapyAge of onsetbusinessBiomarkersAnnals of the American Thoracic Society
researchProduct